Anti-PARP11 / Poly ADP-ribose polymerase 11

Adding 0.2 ml of distilled water will yield a concentration of 500 ug/ml. PARP11 antibody detects Poly(ADP-ribose) polymerase 11, a mono-ADP-ribosyltransferase enzyme that modifies proteins through ADP-ribosylation, influencing their stability, localization, and activity. PARP11 belongs to the PARP family but, unlike canonical poly(ADP-ribose) polymerases, primarily catalyzes mono-ADP-ribose addition. This post-translational modification regulates processes such as nuclear transport, innate immunity, and antiviral defense. The PARP11 antibody is used to study protein modification signaling, interferon responses, and nuclear envelope dynamics.PARP11 is encoded by the PARP11 gene on human chromosome 12q13.11. The protein is approximately 39 kilodaltons and characterized by an N-terminal WWE domain, which mediates protein-protein interactions, and a C-terminal catalytic domain containing the conserved histidine-tyrosine-glutamate motif typical of ADP-ribosyltransferases. PARP11 localizes predominantly to the nuclear envelope and cytoplasmic membrane-associated compartments.The PARP11 antibody detects a 39 kilodalton band by western blot and shows nuclear rim and cytoplasmic punctate staining patterns in immunofluorescence microscopy. PARP11 functions in antiviral defense by ADP-ribosylating host and viral proteins involved in interferon signaling, modulating downstream immune activation. It targets nuclear pore complex components and transport receptors, thereby altering nucleocytoplasmic trafficking during stress or infection. Studies have demonstrated that PARP11 negatively regulates type I interferon responses by promoting degradation of TBK1 and IFNAR1, helping fine-tune innate immune activity.PARP11 also influences ubiquitin-proteasome and SUMOylation pathways through crosstalk with other post-translational modifiers. It plays a role in maintaining nuclear envelope structure and in mitotic progression. Overexpression of PARP11 has been associated with enhanced cell survival under stress, whereas its inhibition sensitizes cells to DNA damage and viral infection. Structural studies suggest that PARP11 recognizes unique NAD+ analogs distinct from other PARP family members, indicating potential for selective drug targeting.Emerging evidence links PARP11 to cancer, viral replication, and neurodegenerative processes. In hepatocellular and colorectal carcinomas, PARP11 overexpression correlates with immune evasion phenotypes and resistance to interferon-based therapies. In neurons, altered ADP-ribosylation by PARP11 may affect axonal transport or synaptic signaling. NSJ Bioreagents provides a validated PARP11 antibody optimized for western blot, immunofluorescence, and nuclear envelope research, enabling detailed analysis of mono-ADP-ribosylation pathways and immune modulation mechanisms.